NanoBio plans new hires as it targets hep B vaccine

Flush from a $14 million upfront payment from GlaxoSmithKline and in hot pursuit of an intranasal therapeutic vaccine for hepatitis B, Ann Arbor, MI-based NanoBio is bursting at the seams.

The biotech company is in the process of hiring a vice president of vaccine research, a director of vaccine research, a director of clinical vaccines, an analytical scientist and a research associate, according to And it's adding new labs and office space to accommodate the swelling workforce.

Using a $300,000 grant from the NIH, NanoBio plans to test the experimental nanoemulsion hepatitis B vaccine on animals and then shift into the clinic to test the shot on people who are already infected by the virus.

"This new intranasal vaccine would have great value as a treatment to reduce the risk of HBV associated liver diseases and deaths globally," NanoBio founder and CEO James Baker says in a statement. "The vaccine is also highly stable at room temperature enabling storage without refrigeration, a factor of great importance in the developing world."

The spinout from the University of Michigan is advancing nanoemulsion technology, which uses tiny droplets to attack the outer membrane of pathogenic organisms. That strategy can work against bacteria, viruses, fungi and spores.

- here's the press release
- here's the story from

Suggested Articles

Moderna is entering an important time, its CEO says. And the company is doing so with a new finance chief from Big Biotech.

Not wanting to be left behind in the COVID-19 vaccine race, Europe is stepping up its efforts secure supplies if any immunizations prove effective.

The Trump administration has selected five COVID-19 vaccines for Operation Warp Speed, the NYT reports, with Big Pharma dominating the list.